Dr. Robert Maki is Professor of Medicine, Pediatrics, and Orthopaedics, and the Steven Ravitch Chair in Pediatric Hematology-Onocology. He has published more than 100 articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and children with sarcomas (connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue) and has an interest in translational research and the biology that leads to different types of sarcomas.
After his MD/PhD at Cornell Medical College in New York City, he was a resident at Brigham and Women's Hospital in Boston before a medical oncology fellowship at Dana-Farber, and was on staff at Dana-Farber before starting at Memorial Sloan-Kettering in 1999. In March, 2011 he moved to the Mount Sinai Medical Center to develop the effort in adult sarcoma therapy and research.
Dr. Maki's efforts at Mount Sinai will be directed towards an increasingly integrative effort sarcoma biology and treatment of sarcomas. His group will conduct clinical trials in adults with sarcomas, and they will also conduct translational studies in sarcoma biology to identify the next possible targets for new drugs to treat sarcomas.
Dr. Maki is also the Director of Translational Oncology at the Sarcoma Alliance for Research through Collaboration (SARC).
PhD, Cornell Graduate School of Medical Sciences
MD, Cornell University Medical College
Residency, Internal Medicine
Brigham and Women's Hospital, Harvard Medical School
Fellowship, Medical Oncology
Dana Farber Cancer Institute
Sarcoma Foundation of America Nobility in Science award
NCI-ASCO Clinical Investigator Team Leadership Award
National Cancer Institute & American Society for Clinical Oncology
Leadership award to develop new clinical and translational studies for sarcoma patients
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Maki during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.